The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Study Boasts Taribavirin Advantage Over Ribavirin for HCV Treatment

Back to News Homepage

Next

29 Potentially Toxic Drugs for Hepatitis C

Achillion Kicks Off Dosing Trial for Hepatitis C Drug

October 6, 2010

Print this page

As Phase II trials to determine a dosing schedule for ACH-1625 begin, Achillion gets closer to a safe and tolerable medication for suppressing the Hepatitis C virus.

Achillion begins anti-hepatitis drug trials

10/01/10

New Haven drug developer Achillion Pharmaceuticals Inc. says it has begun two human clinical trials in the U.S. and Europe to determine the dosing effectiveness of a prototype treatment against the hepatitis C virus.

Some 120 patients with chronic hepatitis C participating in the two double-blind trials — one to run 28 days, the other 12 weeks — will be randomly dosed with small-molecule ACH-1625 drug or with a placebo.

Continue reading this entire article:
http://www.hartfordbusiness.com/news15041.html

No Comments - be the first!
Share
Share

Previous

Study Boasts Taribavirin Advantage Over Ribavirin for HCV Treatment

Back to News Homepage

Next

29 Potentially Toxic Drugs for Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.